INTRODUCTION
cohosh [3] , and glucosamine [4] , and increasing reports of adverse effects of dietary supplements leading to product warnings, withdrawals, and bans, as in the cases of kava [5] , Lipokinetix [6] , and ephedra [7] , respectively. It is difficult to properly ascertain the safety of dietary supplements without a standard and systematic approach to monitoring reports of adverse events. The FDA adverse event monitoring system for dietary supplements has improved surveillance, but the system is still hindered by passive reporting and limited capabilities to investigate adverse events through retrospective data collection. Because of these limitations, it could take months or years for an association between a harmful supplement and a new health risk to be recognized.
Increasing reports of adverse events associated with dietary supplements raise concern among consumers, health-care providers, regulators, and lawmakers about the safety of these products. Although media and medical journal reports of adverse health effects of dietary supplements are increasingly common, many reports are neither well documented nor substantiated by scientific evidence. In many of the reported cases, a clear association between use of the product and the suspected adverse reaction is not evident. Episodic case reports of adverse effects have been interpreted by some as evidence of the dangers of dietary supplements, but by others as confirmation that such cases are rare given their widespread use. With passage of the Dietary Supplement and Nonprescription Drug Consumer Protection Act in 2006, manufacturers of dietary supplements will be mandated to report all complaints of serious adverse events to the FDA within 15 business days.
In 2004, the Institute of Medicine Committee on the Framework for Evaluating the Safety of Dietary Supplements recommended to the FDA that a prospective systematic monitoring and tracking mechanism for dietary supplement ingredients should be maintained and refined, and that the FDA should work with the nation's poison control centers as a source of adverse event reports [8] . American Association of Poison Control Centers (AAPCC) annual reports of poisoning exposures provide summary data on adverse events related to a variety of substances, including drugs, chemicals, animals, plants, and dietary supplements. However, reliance on retrospective reports of poison center statistics to evaluate dietary supplement safety has a number of limitations including inaccurate coding of cases, misattributing co-ingestant-related symptoms to dietary supplements, incomplete product information, lack of confirmatory laboratory testing, and inadequate follow-up.
In this report, we describe the results of a 1-year prospective surveillance study of dietary supplement-related calls made to one regional poison control center. Key elements of the surveillance project included prompt follow-up of symptomatic cases, laboratory analysis of implicated dietary supplements and patient specimens, causality assessment by a case review panel, and quarterly summary reports made to the FDA for regulatory oversight.
METHODS
In collaboration with the FDA Center for Food Safety and Nutrition (CFSAN) we designed and conducted a 1-year surveillance study of dietary supplement-related calls made to the California Poison Control System, San Francisco Division (CPCS-SF) from January 1 through December 31, 2006. All calls involving products regulated as dietary supplements were included. Excluded were traditional remedies such as Chinese herbal and Ayurvedic medicines, homeopathic products, and traditional food supplements such as beverages and energy bars because these products fall under different regulatory jurisdiction than dietary supplements.
The overall goal of this project was to apply a consistent, objective approach in collection and evaluation of reported adverse events to be able to determine whether the event was related to the exposure (i.e., causation) and also to monitor trends in dietary supplement adverse event reporting.
All calls made to the CPCS-SF that involved dietary supplements were collected by poison center staff and medical toxicology fellows. Cases that did not involve symptoms were tallied but not further investigated. Cases that involved symptoms were promptly investigated. Follow-up calls were made to health-care providers, and in some cases patients and family members, for additional information and to request shipment of patient urine and plasma specimens and dietary supplement product samples to our laboratories for analysis, when appropriate.
Symptomatic cases were redacted and summarized for causality assessment by a multidisciplinary case review panel comprised of 5 individuals with expertise in dietary supplements. Each panel member reviewed and scored case summaries for causation, relying on individual expertise, published literature, and other personal resources. Uniform guidelines were utilized for causality assessment based on the World Health Organization (WHO) Classification for Adverse Drug Reactions. A description of the WHO causality categories is listed in Table 1 . Face-to-face meetings of the principal investigator (CH) and panel members (coauthors) were held quarterly to determine causality scores for each case by consensus of the panel. A symptom severity score was assigned for adverse events that were rated on causality assessment as possible, probable, or very likely/certain. Severity scores were based on AAPCC definitions using criteria for symptom severity and required treatment and include no effect, minor, moderate, severe, and death.
Quarterly reports were submitted to FDA CFSAN, which included a list of asymptomatic calls, case summaries of calls involving symptoms, causality and severity ratings for adverse events, results of laboratory testing, and reports of observed trends in dietary supplement adverse events.
This study was approved by the University of California, San Francisco Committee on Human Research with a waiver of patient informed consent.
RESULTS
During the 1-year period from January 1 to December 31, 2006, a total of 275 calls about dietary supplements were received by the CPCS-SF, which comprised approximately 0.4% of the 75,390 calls made to the poison center division during the year. Of these calls, 112 (40.7%) concerned persons who were symptomatic and 163 (59.3%) involved dietary supplement exposures in individuals who had no symptoms or consisted of information requests about supplements. The types of dietary supplements most commonly involved in asymptomatic calls included melatonin (29%); caffeine-containing multicomponent products (12%); glucosamine (11%); omega-3/fish oils (6%); echinacea (5%); amino acids (4%); and 5-hydroxytryptophan (5-HTP), saw palmetto, yohimbe, and black cohosh (2% each). Unintentional or accidental exposures comprised 87% of asymptomatic dietary supplement calls; children under age 5 years accounted for most of these.
Among the 112 calls that involved individuals experiencing signs or symptoms of toxicity, 20 cases (18%) involved intentional misuse or overdose, while the remaining 82% of adverse events occurred with apparently appropriate use of the dietary supplement. The consensus on causality likelihood of symptomatic cases by the case review panel concluded that 2% were very likely or certain; 30% were probable; 34% were possible; and 20% were unlikely to be attributed to the use of the dietary supplement. Cases judged to be likely, probably, or possibly related to supplement use will be described as "related" in the remainder of this report. In 14% of cases there was insufficient information to adequately assess causation; these cases were rated as unclassifiable.
Eight adverse events related to dietary supplements required hospital admission, including 3 patients admitted to intensive care units. There was one death due to stroke possibly associated with concomitant use of several caffeine-and yohimbe-containing dietary supplements (inset, Figure 1 ). The types of related adverse events grouped by body system along with the suspected causative Lab Blood Pressure Control, and Relacore for fat burning/weight loss.
I He was observed to "black out" with a possible seizure.
I Upon presentation to a hospital emergency department, he was minimally responsive with right-sided paralysis and a left gaze preference. Vital signs included: Blood pressure, 125/61 mm Hg; heart rate, 62/min, Serum potassium was 3.2 mEq/L, and other laboratory values were normal.
I Computed topography (CT) of the head showed infarction of the left middle cerebral artery. He had a possible history of hypertension but was not taking any medications. A small atrial-septal defect was seen on echocardiogram.
I His mental status continued to decline. On Day 2, he was declared brain dead based on a brain blood flow study. No autopsy was performed, and his death was ruled due to embolic stroke.
I Supplement Ingredients:
G Shrink Wrap contains dandelion root (500 mg), uva ursi (250 mg), juniper berry (200 mg), buchu leaf (150 mg).
G Blood Pressure Control contains C-12 peptide (100 mg).
G Relacore contains Relacortin (266 mg), magnolia bark, passion flower, scutellaria, niacinamind, DHEA, panax ginseng, pinellia, poria, jujuba, perilla, phosphotidylserine (quantities not listed).
G Xenadrine NRG 8 hour contains Norambolide (sclareolide extract), thermoxanthin (proprietary blend of L-tyrosine, coffee bean, green tea, cocoa seed, yerba mate and caffeine (quantities not listed).
G RedLine Fat Incinerator contains caffeine, evodiamine, N-acetyl-L-tyrosine, guggulsterone, yerba mate, green tea 5-hydroxy-L-tryptophan, cAMP, vinpocetine, yohimbine HCl (quantities not listed).
I Samples of RedLine Fat Incinerator were analyzed by gas chromatography/mass spectrometry (GC-MS), which confirmed the presence of yohimbine, and liquid chromatography-tandem mass spectrometry (LC-MS/MS), which found 85 mg caffeine per capsule (255 mg per serving ~ equivalent to 3 cups coffee).
dietary supplement ingredient are shown in Table 2 . Sympathomimetic toxicity was the most common type of adverse event reported among related cases. The supplement type, severity of reported adverse events, and number of related dietary supplement cases are summarized in Table 3 . Multicomponent dietary supplements are listed by the ingredient believed to be responsible for the reported symptoms. Supplements that contained both caffeine and yohimbe are listed as yohimbe multicomponent products. Caffeine single-and multicomponent dietary supplements accounted for 47%, and yohimbe single-and multicomponent products accounted for 18% of supplement-related symptomatic cases. The multicomponent caffeine and yohimbe products involved in related cases are listed by brand name, listed ingredients, and frequency of calls in Table 4 . Suspected drug-herb interactions occurred in 6 cases, including yohimbe co-ingested with buproprion (n ϭ1) and methamphetamine (n ϭ3), and additive anticoagulant/antiplatelet effects of nonsteroidal anti-inflammatory drugs taken with fish oils (n ϭ1) and ginkgo (n ϭ1).
Laboratory analysis of dietary supplements and patient urine or plasma was performed in 9 symptomatic cases. In 5 cases, supplement toxicity was ruled unlikely when analytical testing was negative for suspected causative supplement ingredients or chemical adulterants. In 4 cases, a substance with known pharmacological activity that could plausibly be linked to the adverse event was identified, including the cardiovascular stimulants berberine, yohimbine, and caffeine, and high concentrations of Vitamin E, which has anticoagulant effects [9] .
DISCUSSION
In this paper, we have described a systematic approach for surveillance of poison control center calls as a method for monitoring and tracking dietary supplement adverse events that is consistent with Institute of Medicine recommendations for evaluating the safety of dietary supplements. Poison control centers historically have played an important role in rapid detection of new health risks related to consumer products with prompt dissemination of information to health-care professionals, regulatory officials, and the public. Active surveillance and follow-up of poison center reports of adverse dietary supplement events allows for detection of new signals of potentially harmful products that may be missed by other spontaneous reporting systems.
Although the majority of supplement-related adverse events were minor, clinically significant toxic effects were more frequently reported with caffeine-containing multicomponent supplements than with any other type of supplement. Moderate and severe adverse events most often involved sympathomimetic symptoms attributed to the stimulant actions of caffeine-and yohimbe-containing products. There was one death due to stroke that was possibly attributed to use of multiple caffeine-and yohimbe-containing supplements in the setting of strenuous physical exertion. Detection of several similar adverse events raises concern about these stimulant products that warrants further investigation.
As illustrated in Table 4 , adverse events attributed to stimulantcontaining supplements involved a large number of different brands with a wide variety of ingredients. For the majority of products, the concentrations of active stimulants, particularly caffeine, are not provided in the ingredient list on the label. Although the dose equivalent of yohimbine is listed frequently on the label, the quantity of other stimulant alkaloids such as synephrine, tyramine, and phenethylamine is rarely provided. Listings of so-called "proprietary" botanical blends of amino acids, bioamines, and methylxanthines in total gram quantities fail to provide adequate information for consumers and health-care providers about dose amounts of potentially potent stimulants. Although few scientific studies have been conducted on the clinical effects and interactions of multicomponent stimulant dietary supplements, preliminary human data indicates that combinations of caffeine with other herbal stimulants intensify cardiovascular and central nervous system effects [10] . These products are marketed for weight loss and athletic performance enhancement and thus are likely to be used under conditions of cardiovascular stress (strenuous exercise) and by individuals with possible underlying cardiovascular risks (hypertension, coronary artery disease, diabetes). Further investigation is needed to determine if the sympathomimetic adverse effects of stimulantcontaining dietary supplements observed in this study signal a potentially significant risk of toxicity for consumers.
The largest number of calls related to specific products involved Zantrex 3 (n ϭ 7), and Trim Spa (n ϭ 5), however, we could not determine whether this observation suggests greater risk of toxicity or higher prevalence of use of these products relative to other brands. Product sales information and epidemiological data on consumer use rates are needed to ascertain relative risk of individual products as well as to compare adverse-event incidence between types of supplements.
Possible drug-supplement interactions were observed in several cases, including 3 cases of yohimbe use in the context of recent or concurrent use of methamphetamine, and one case of combined use of yohimbe with the antidepressant drug, buproprion. Sympathomimetic stimulants such as cocaine and
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JOURNAL OF MEDICAL TOXICOLOGY I VOLUME 4, NUMBER 2 I JUNE 2008 methamphetamine induce short-term erectile dysfunction due to vasoconstriction, and self-treatment with sildenafil and similar drugs has been reported [11] . It may be that use of yohimbe as a sexual enhancer is popularly promoted among illicit stimulant users, and represents a potentially risky drug-supplement combination.
In addition to sympathomimetic stimulant effects of supplements, several other trends in supplement-related symptoms were observed ( Table 2) , including some potentially novel associations. A number of reports of muscle pain and cramping with elevated creatine kinase and, in some cases, rhabdomyolysis were reported with several different supplements, frequently taken in combination with other supplements and medications. Complaints of muscle pain and cramping were reported with various multicomponent dietary supplements containing creatine, amino acids (taurine, l-carnitine, glutamine, L-tyrosine, and L-arginine), Morinda Citrifolia (Noni), yohimbe, saw palmetto, caffeine, and Citrus aurantium. Creatine has been reported to cause muscle cramping and, rarely, rhabdomyolysis [12, 13] ; however, some recent clinical studies do not support this association [14, 15] . Although definitive causality could not be established in our cases because of a lack of substantiating scientific evidence, the frequency of similar reports raises questions about possible muscle toxicity of some dietary supplements.
Two cases of bleeding were reported with combined use of a nonsteroidal anti-inflammatory drug with ginkgo biloba and fish oils, two dietary supplements that are known to have anticoagulant effects [16] . In one case, bleeding was spontaneous and minor (epistaxis), but the second case (post-spinal surgical hemorrhage) was more serious and required hemostatic therapy. Other case reports of impaired coagulation due to dietary supplement use have raised concerns among physicians about increased risk of perioperative hemorrhage [9, 17] . Some clinicians now advise patients to stop all herbal medicines and supplements for at least 1 week prior to scheduled surgery [18] .
The approach used in this study-including active surveillance of poison center calls with prompt case follow-up, committee review for causation analysis, and substantiation of exposures through product and specimen analysis-is a first step towards implementation of the IOM recommendations for dietary supplement safety. This approach could be implemented at other poison control centers, and could also serve as a model for systematic tracking of poison center reports of adverse drug events, medication errors, and drug interactions.
A notable limitation of this study was incomplete case followup, which prevented causality assessment in 14% of cases. This frequently occurred when the poison center staff didn't identify a case of dietary supplement toxicity and failed to obtain adequate information or request samples of dietary supplement products. Other limitations included possible under-and overreporting due to inaccurate case coding or inclusion of alternative medicine products that were not dietary supplements. These limitations lessened over the course of the project period with staff training and standardization of inclusion criteria. Objective assessment of causality by expert clinical toxicologists using a standardized rating system and analytical testing of dietary supplement products strengthened the quality of information derived from poison center adverse event reports.
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